Abstract
Neointima (NI) formation following arterial bypass graft surgery or balloon angioplasty is considered central to subsequent failure after these procedures. The NI promotes accelerated atherogenesis, re-occlusion and thrombosis resulting in a failure rate as high as 50% within 1-10 years. Furthermore, despite the relative success of statins and drug eluting stents, drugs that reduce the failure rate have as yet not been implemented. In turn, animal models are a crucial means of testing potential interventions, in particular, drugs. The objective of this review therefore is to provide a survey of all the possible models that can be used to explore the effects of drugs on NI formation. The review will focus on the most commonly used of species, namely the rat, rabbit, mouse, pig and dog.
Keywords: Neointima, bypass graft, balloon angioplasty, stent, restenosis, atherosclerosis, animal model
Current Vascular Pharmacology
Title: Animal Models for Studying Neointima Formation
Volume: 8 Issue: 2
Author(s): Jamie Y. Jeremy and Anita C. Thomas
Affiliation:
Keywords: Neointima, bypass graft, balloon angioplasty, stent, restenosis, atherosclerosis, animal model
Abstract: Neointima (NI) formation following arterial bypass graft surgery or balloon angioplasty is considered central to subsequent failure after these procedures. The NI promotes accelerated atherogenesis, re-occlusion and thrombosis resulting in a failure rate as high as 50% within 1-10 years. Furthermore, despite the relative success of statins and drug eluting stents, drugs that reduce the failure rate have as yet not been implemented. In turn, animal models are a crucial means of testing potential interventions, in particular, drugs. The objective of this review therefore is to provide a survey of all the possible models that can be used to explore the effects of drugs on NI formation. The review will focus on the most commonly used of species, namely the rat, rabbit, mouse, pig and dog.
Export Options
About this article
Cite this article as:
Jeremy Y. Jamie and Thomas C. Anita, Animal Models for Studying Neointima Formation, Current Vascular Pharmacology 2010; 8 (2) . https://dx.doi.org/10.2174/157016110790887027
DOI https://dx.doi.org/10.2174/157016110790887027 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part I))
Current Molecular Pharmacology Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Periodontitis, Endothelial Dysfunction and Atherosclerosis
Vascular Disease Prevention (Discontinued) Pharmacogenetics of the Antiplatelet Effect of Aspirin
Current Pharmaceutical Design Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets Fatty Acids and Obesity
Current Pharmaceutical Design Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets From Traditional European Medicine to Discovery of New Drug Candidates for the Treatment of Dementia and Alzheimer's Disease: Acetylcholinesterase Inhibitors
Current Medicinal Chemistry Editorial (Hot Topic: The New Kids on the Block: Oral Direct IIa and Xa Inhibitors Enter the Proscenium of Anticoagulation Treatment)
Current Clinical Pharmacology MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Antioxidants as Potentially Safe Antidotes for Organophosphorus Poisoning
Current Enzyme Inhibition Cardioactive Agents from Plants
Mini-Reviews in Medicinal Chemistry An Overview of Compounds Derived from the Shikimate and Phenylpropanoid Pathways and Their Medicinal Importance
Mini-Reviews in Medicinal Chemistry Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
Current Vascular Pharmacology The Role of Angiogenesis in Coronary Artery Disease: A Double-Edged Sword: Intraplaque Angiogenesis in Physiopathology and Therapeutic Angiogenesis for Treatment
Current Pharmaceutical Design Application of Hematopoietic Cells to Therapeutic Angiogenesis
Current Pharmaceutical Design